Mantle cell lymphoma (MCL) is a blood cancer that is rare and occurs due to the too much growth of lymphocytes. Mantle cell lymphoma occurs as a result of the formation of tumors in the lymph nodes, which enters the blood and spreads to the spleen, bone marrow, liver and digestive tract.
The global mantle cell lymphoma market is expected to grow significantly during the forecast period due to increasing incidence of mantle cell lymphoma. Based on therapy type, the mantle cell lymphoma market is segmented into chemo therapy, targeted therapy and radio therapy. The targeted therapy is expected to grow significantly in this segment.
The impact of COVID-19 on mantle cell lymphoma market has started to be felt. The breakout of this disease led to lockdowns across globe which has slowed down the growth of many markets. Mantle cell lymphoma market is no different. However, the market is expected to catch up and grow rapidly in the forecast years.
The increasing prevalence of mantle cell lymphoma is expected to drive the growth of the mantle cell lymphoma market. Increasing R&D activities in the healthcare sector resulting in a robust product pipeline may also contribute to the growth of the mantle cell lymphoma market. Introduction of targeted therapies is also expected to boost the growth of the mantle cell lymphoma market.However, serious side effects of drugs anaemia, neutropenia and diarrhea may restrict the growth of the market.
Mantle cell lymphoma market is expected to witness substantial growth as a result of increasing incidence of mantle cell lymphoma globally during the forecast period.
Based on therapy type, the market is segmented into targeted therapy, chemotherapy and radio therapy. In this segment, targeted therapy is expected to undergo maximum growth during the forecast period. This is because the chemotherapy may also kill the normal cells which may have more side effects.
Based on distribution channel, the global mantle cell lymphoma market is segmented intohospitals, research centers and others. The hospital segment is expected to continue to contribute huge revenues in this segment.
Geographically, themantle cell lymphoma marketis segmented into sevenregions viz. East Asia, South Asia, Latin America,EuropeOceania,North AmericaandMiddle East &Africa.North America is expected to dominate the global market for mantle cell lymphoma due to rising incidence of mantle cell lymphoma in this region.
The presence of increased no. of research and development may also contribute to the growth of the mantle cell lymphoma market in this region. Europe is expected to have the second largest market for global mantle cell lymphoma due to developed healthcare structure in this region.
However, East Asia is expected to witness a substantial growth in the mantle cell lymphoma marketdue to availability of funds for research and development.On the other hand, South Asia is anticipated to experience fastest growth in the mantle cell lymphoma market as a result of increasing incidence of mantle cell lymphoma. In the Middle East and Africa the market growth is expected to be limited due to underdeveloped infrastructure, slow economic growth and lower access to technological advancement.
Some of the players identified in the mantle cell lymphoma marketinclude:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Tentatively, the global mantle cell lymphoma markethas been segmented on the basis of therapy type, end-user and region.
Therapy type
End users
Region
Explore Similar Insights
Mantle Cell Lymphoma Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
